Business
Roche Pays $100 Million for an RNA Drug That Targets Belly Fat, Not Appetite
The deal with China’s Rona Therapeutics, worth up to about $1 billion, gives Roche a gene-silencing drug aimed at ALK7, a switch in fat cells. It is a bet on what comes after GLP-1s — and it is still early.